Article
Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations.
Pharmacogenomics - 1 Mar 2003
Rudnicki M, Mayer G
Abstract excerpt
Angiotensin converting enzyme (ACE) inhibitors preserve native kidney function in patients with renal disease better than other antihypertensive drugs, most likely because they more effectively reduce proteinuria. The plasma concentration of the ACE inhibitors target is, at least in part, under genetic control. A polymorphism of the ACE gene based on the presence or absence of a 287 base pair element in intron 16...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.